The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...

Capital structure describes the mix of a firm's long-term capital—a mix of debt and equity—that it uses to fund its ongoing operations and future growth. A company's capital structure is ...

Patritumab deruxtecan (HER3-DXd), a HER3 directed ADC, ifinatamab deruxtecan (I-DXd), a B7-H3 directed ADC, and raludotatug deruxtecan (R-DXd), a CDH6 directed ADC, are being jointly developed and ...

TROPION-Lung10 is evaluating Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus rilvegostomig as first-line treatment for advanced or metastatic nonsquamous NSCLC with high PD-L1 ...

Patritumab deruxtecan starts phase 3 Daiichi Sankyo meanwhile has started a phase 3 trial of another ADC – patritumab deruxtecan – comparing the drug to chemotherapy as a second-line therapy ...

The antibody-drug conjugate (ADC) patritumab deruxtecan (HER3-DXd) is a promising treatment for EGFR inhibitor-resistant disease. "The hypothesis is that tumors that have resistance to EGFR TKIs ...

Three phase 3 trials will assess datopotamab deruxtecan-based treatments in patients with nonsquamous non-small cell lung cancer. The first patients with locally advanced or metastatic nonsquamous non ...

Patritumab deruxtecan, which is currently leading the anti-HER3 pipeline, has shown efficacy in heavily pre-treated patients with EGFR-mutated NSCLC previously treated with multiple EGFR ...

Study results show that a portable breath analysis device designed for early detection of non–small cell lung cancer may distinguish between patients with the disease and healthy individuals ...